NR 565 Final Exam Prep Document | 2026/2027 Edition | 200
Verified Questions - 189 Questions with Answers
NR 565 Advanced Pharmacology Fundamentals Final Exam 2026-189 QUESTIONS AND ANSWERS ALREADY
GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive practice exam is meticulously designed for nursing students preparing for the NR
565 Advanced Pharmacology Fundamentals final exam. It features 200 verified questions that mirror
the format and content of the actual exam, ensuring a thorough review of essential pharmacological
principles. Each question is accompanied by a detailed rationale to reinforce learning and promote
critical thinking. This resource is an indispensable tool for mastering advanced pharmacology and
achieving a top score.
Key Features:
Pharmacokinetics and Pharmacodynamics
Autonomic Nervous System Drugs
Cardiovascular Pharmacology
Endocrine and Metabolic Agents
Antimicrobial Therapy
Neurological and Psychiatric Medications
Updates for 2026:
- Revised to align with the latest 2026/2027 AACN and NCSBN guidelines.
- Incorporated recent FDA drug approvals and safety alerts.
- Enhanced rationales with evidence-based practice references.
- Added new questions on emerging pharmacogenomic considerations.
- Updated answer explanations to reflect current clinical protocols.
Abstract:
The NR 565 Advanced Pharmacology Fundamentals Final Exam Practice Test is a rigorous, 200-question
assessment tool designed to evaluate and enhance the pharmacological knowledge of graduate nursing students.
Covering a broad spectrum of topics from drug metabolism to complex therapeutic regimens, this practice test
challenges students to apply advanced concepts in clinical scenarios. Each question is crafted to reflect the depth
and breadth of the actual exam, with rationales that explain both correct and incorrect options, fostering a deeper
understanding of pharmacotherapeutic decision-making. This resource is essential for students seeking to
consolidate their learning, identify knowledge gaps, and build confidence for exam success. By engaging with this
material, students will be well-prepared to excel in the final examination and in their future advanced practice
roles.
Keywords:
NR 565, Advanced Pharmacology, Final Exam, Practice Test, 200 Questions, Rationales, Nursing Education,
Pharmacotherapeutics
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is indicated, followed
by a comprehensive rationale explaining why it is correct and why the other options are incorrect. This format
reinforces critical thinking and clinical reasoning skills.
Compliance Checklist:
Aligned with the latest 2026/2027 curriculum standards
Includes evidence-based rationales for all answers
Page 1
, Covers all major content areas of the NR 565 final exam
Verified by subject matter experts for accuracy
Updated to reflect current clinical guidelines and drug information
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, Distribution, Metabolism, 15%
Pharmacodynamics Excretion, Receptor Theory
Autonomic Nervous System 31-60 Cholinergic Agonists, Anticholinergics, 15%
Drugs Adrenergic Agonists, Adrenergic Blockers
Cardiovascular Pharmacology 61-90 Antihypertensives, Antiarrhythmics, 15%
Anticoagulants, Lipid-Lowering Agents
Endocrine and Metabolic Agents 91-120 Insulin, Oral Hypoglycemics, Thyroid 15%
Medications, Corticosteroids
Antimicrobial Therapy 121-150 Antibiotics, Antivirals, Antifungals, 15%
Antimycobacterials
Neurological and Psychiatric 151-180 Antiepileptics, Antidepressants, 15%
Medications Antipsychotics, Anxiolytics
Special Populations and 181-200 Pediatrics, Geriatrics, Pregnancy, Genetic 10%
Pharmacogenomics Variations
Page 2
,Q1. A patient with chronic kidney disease (CrCl 25 mL/min) requires antibiotic
therapy for a severe infection. Which agent requires the most substantial dosage
adjustment, and what is the primary pharmacokinetic reason?
A. Ceftriaxone; extensive hepatic metabolism
B. Vancomycin; primarily renal elimination
C. Linezolid; renal tubular secretion
D. Ciprofloxacin; extensive tissue binding
Correct Answer: B. Vancomycin; primarily renal elimination
Rationale: Vancomycin is predominantly excreted unchanged by the kidneys, so renal
impairment necessitates significant dose reduction and therapeutic drug monitoring to
avoid toxicity. Ceftriaxone is primarily hepatically eliminated and requires minimal
adjustment. Linezolid is mostly metabolized, and ciprofloxacin requires moderate
adjustment but not as substantial as vancomycin.
Why Wrong:
A - Ceftriaxone is mainly hepatically cleared, so renal impairment has minimal
impact.
C - Linezolid is metabolized hepatically, not renally secreted to a significant degree.
D - Ciprofloxacin requires adjustment but to a lesser extent than vancomycin due to
dual elimination.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 66.
Q2. A patient on warfarin is started on a new medication. Three weeks later, the INR
increases from 2.5 to 4.8. Which drug is most likely responsible, and what is the
mechanism?
A. Rifampin; CYP3A4 induction
B. Fluconazole; CYP2C9 inhibition
C. Phenytoin; CYP2C19 induction
D. Omeprazole; CYP1A2 inhibition
Correct Answer: B. Fluconazole; CYP2C9 inhibition
Rationale: Fluconazole is a potent inhibitor of CYP2C9, the enzyme that metabolizes the
S-enantiomer of warfarin. Inhibition leads to increased warfarin levels and elevated INR,
increasing bleeding risk. Rifampin and phenytoin are inducers that would decrease INR;
omeprazole's effect is less significant.
Why Wrong:
A - Rifampin induces CYP enzymes, reducing warfarin effect and INR.
C - Phenytoin induces CYP enzymes, potentially decreasing warfarin levels.
D - Omeprazole inhibits CYP2C19, but this is not the primary pathway for warfarin
metabolism.
Page 3
, Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 36.
Q3. A patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min)
needs an antihyperglycemic agent. Which medication is contraindicated due to
increased risk of lactic acidosis?
A. Sitagliptin
B. Metformin
C. Empagliflozin
D. Glipizide
Correct Answer: B. Metformin
Rationale: Metformin is contraindicated when eGFR falls below 30 mL/min (and often not
initiated below 45) because of the risk of lactic acidosis. Sitagliptin requires dose
adjustment but is not contraindicated; empagliflozin is used with reduced eGFR but not at
this stage; glipizide is safe but may require caution.
Why Wrong:
A - Sitagliptin is renally cleared but not contraindicated at this eGFR, only
dose-adjusted.
C - Empagliflozin is not recommended below eGFR 30 but is not associated with
lactic acidosis.
D - Glipizide is hepatically metabolized and safe in renal impairment.
Reference: American Diabetes Association. (2025). Standards of Care in Diabetes-2025.
Diabetes Care, 48(Suppl 1).
Q4. Which of the following best explains why a patient with heart failure and reduced
ejection fraction may experience improved symptoms with sacubitril/valsartan
compared to an ACE inhibitor alone?
A. Combined inhibition of ACE and angiotensin II receptor
B. Inhibition of neprilysin while blocking AT1 receptors
C. Blockade of aldosterone receptors and beta-1 receptors
D. Selective vasodilation of venous capacitance vessels
Correct Answer: B. Inhibition of neprilysin while blocking AT1 receptors
Rationale: Sacubitril inhibits neprilysin, increasing natriuretic peptides, while valsartan
blocks AT1 receptors. This dual mechanism reduces neurohormonal activation and
enhances beneficial effects in heart failure. ACE inhibition is not part of
sacubitril/valsartan; it does not block aldosterone or beta receptors.
Why Wrong:
A - Sacubitril/valsartan does not inhibit ACE; it inhibits neprilysin.
C - It does not block aldosterone receptors or beta-1 receptors.
D - Its vasodilation is not selective to veins; it affects both arteries and veins.
Page 4
Verified Questions - 189 Questions with Answers
NR 565 Advanced Pharmacology Fundamentals Final Exam 2026-189 QUESTIONS AND ANSWERS ALREADY
GRADED A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive practice exam is meticulously designed for nursing students preparing for the NR
565 Advanced Pharmacology Fundamentals final exam. It features 200 verified questions that mirror
the format and content of the actual exam, ensuring a thorough review of essential pharmacological
principles. Each question is accompanied by a detailed rationale to reinforce learning and promote
critical thinking. This resource is an indispensable tool for mastering advanced pharmacology and
achieving a top score.
Key Features:
Pharmacokinetics and Pharmacodynamics
Autonomic Nervous System Drugs
Cardiovascular Pharmacology
Endocrine and Metabolic Agents
Antimicrobial Therapy
Neurological and Psychiatric Medications
Updates for 2026:
- Revised to align with the latest 2026/2027 AACN and NCSBN guidelines.
- Incorporated recent FDA drug approvals and safety alerts.
- Enhanced rationales with evidence-based practice references.
- Added new questions on emerging pharmacogenomic considerations.
- Updated answer explanations to reflect current clinical protocols.
Abstract:
The NR 565 Advanced Pharmacology Fundamentals Final Exam Practice Test is a rigorous, 200-question
assessment tool designed to evaluate and enhance the pharmacological knowledge of graduate nursing students.
Covering a broad spectrum of topics from drug metabolism to complex therapeutic regimens, this practice test
challenges students to apply advanced concepts in clinical scenarios. Each question is crafted to reflect the depth
and breadth of the actual exam, with rationales that explain both correct and incorrect options, fostering a deeper
understanding of pharmacotherapeutic decision-making. This resource is essential for students seeking to
consolidate their learning, identify knowledge gaps, and build confidence for exam success. By engaging with this
material, students will be well-prepared to excel in the final examination and in their future advanced practice
roles.
Keywords:
NR 565, Advanced Pharmacology, Final Exam, Practice Test, 200 Questions, Rationales, Nursing Education,
Pharmacotherapeutics
Answer Format:
Each question is presented in multiple-choice format with four options. The correct answer is indicated, followed
by a comprehensive rationale explaining why it is correct and why the other options are incorrect. This format
reinforces critical thinking and clinical reasoning skills.
Compliance Checklist:
Aligned with the latest 2026/2027 curriculum standards
Includes evidence-based rationales for all answers
Page 1
, Covers all major content areas of the NR 565 final exam
Verified by subject matter experts for accuracy
Updated to reflect current clinical guidelines and drug information
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-30 Absorption, Distribution, Metabolism, 15%
Pharmacodynamics Excretion, Receptor Theory
Autonomic Nervous System 31-60 Cholinergic Agonists, Anticholinergics, 15%
Drugs Adrenergic Agonists, Adrenergic Blockers
Cardiovascular Pharmacology 61-90 Antihypertensives, Antiarrhythmics, 15%
Anticoagulants, Lipid-Lowering Agents
Endocrine and Metabolic Agents 91-120 Insulin, Oral Hypoglycemics, Thyroid 15%
Medications, Corticosteroids
Antimicrobial Therapy 121-150 Antibiotics, Antivirals, Antifungals, 15%
Antimycobacterials
Neurological and Psychiatric 151-180 Antiepileptics, Antidepressants, 15%
Medications Antipsychotics, Anxiolytics
Special Populations and 181-200 Pediatrics, Geriatrics, Pregnancy, Genetic 10%
Pharmacogenomics Variations
Page 2
,Q1. A patient with chronic kidney disease (CrCl 25 mL/min) requires antibiotic
therapy for a severe infection. Which agent requires the most substantial dosage
adjustment, and what is the primary pharmacokinetic reason?
A. Ceftriaxone; extensive hepatic metabolism
B. Vancomycin; primarily renal elimination
C. Linezolid; renal tubular secretion
D. Ciprofloxacin; extensive tissue binding
Correct Answer: B. Vancomycin; primarily renal elimination
Rationale: Vancomycin is predominantly excreted unchanged by the kidneys, so renal
impairment necessitates significant dose reduction and therapeutic drug monitoring to
avoid toxicity. Ceftriaxone is primarily hepatically eliminated and requires minimal
adjustment. Linezolid is mostly metabolized, and ciprofloxacin requires moderate
adjustment but not as substantial as vancomycin.
Why Wrong:
A - Ceftriaxone is mainly hepatically cleared, so renal impairment has minimal
impact.
C - Linezolid is metabolized hepatically, not renally secreted to a significant degree.
D - Ciprofloxacin requires adjustment but to a lesser extent than vancomycin due to
dual elimination.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 66.
Q2. A patient on warfarin is started on a new medication. Three weeks later, the INR
increases from 2.5 to 4.8. Which drug is most likely responsible, and what is the
mechanism?
A. Rifampin; CYP3A4 induction
B. Fluconazole; CYP2C9 inhibition
C. Phenytoin; CYP2C19 induction
D. Omeprazole; CYP1A2 inhibition
Correct Answer: B. Fluconazole; CYP2C9 inhibition
Rationale: Fluconazole is a potent inhibitor of CYP2C9, the enzyme that metabolizes the
S-enantiomer of warfarin. Inhibition leads to increased warfarin levels and elevated INR,
increasing bleeding risk. Rifampin and phenytoin are inducers that would decrease INR;
omeprazole's effect is less significant.
Why Wrong:
A - Rifampin induces CYP enzymes, reducing warfarin effect and INR.
C - Phenytoin induces CYP enzymes, potentially decreasing warfarin levels.
D - Omeprazole inhibits CYP2C19, but this is not the primary pathway for warfarin
metabolism.
Page 3
, Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 36.
Q3. A patient with type 2 diabetes and chronic kidney disease (eGFR 35 mL/min)
needs an antihyperglycemic agent. Which medication is contraindicated due to
increased risk of lactic acidosis?
A. Sitagliptin
B. Metformin
C. Empagliflozin
D. Glipizide
Correct Answer: B. Metformin
Rationale: Metformin is contraindicated when eGFR falls below 30 mL/min (and often not
initiated below 45) because of the risk of lactic acidosis. Sitagliptin requires dose
adjustment but is not contraindicated; empagliflozin is used with reduced eGFR but not at
this stage; glipizide is safe but may require caution.
Why Wrong:
A - Sitagliptin is renally cleared but not contraindicated at this eGFR, only
dose-adjusted.
C - Empagliflozin is not recommended below eGFR 30 but is not associated with
lactic acidosis.
D - Glipizide is hepatically metabolized and safe in renal impairment.
Reference: American Diabetes Association. (2025). Standards of Care in Diabetes-2025.
Diabetes Care, 48(Suppl 1).
Q4. Which of the following best explains why a patient with heart failure and reduced
ejection fraction may experience improved symptoms with sacubitril/valsartan
compared to an ACE inhibitor alone?
A. Combined inhibition of ACE and angiotensin II receptor
B. Inhibition of neprilysin while blocking AT1 receptors
C. Blockade of aldosterone receptors and beta-1 receptors
D. Selective vasodilation of venous capacitance vessels
Correct Answer: B. Inhibition of neprilysin while blocking AT1 receptors
Rationale: Sacubitril inhibits neprilysin, increasing natriuretic peptides, while valsartan
blocks AT1 receptors. This dual mechanism reduces neurohormonal activation and
enhances beneficial effects in heart failure. ACE inhibition is not part of
sacubitril/valsartan; it does not block aldosterone or beta receptors.
Why Wrong:
A - Sacubitril/valsartan does not inhibit ACE; it inhibits neprilysin.
C - It does not block aldosterone receptors or beta-1 receptors.
D - Its vasodilation is not selective to veins; it affects both arteries and veins.
Page 4
